



6 May 2020

ASX ANNOUNCEMENT

ImpediMed Secures US Government COVID-19 CARES Act Loan

Brisbane, Australia and Carlsbad, California – ImpediMed Limited (ASX:IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), is pleased to announce the receipt of loan proceeds of US\$1,140,202 pursuant to the Paycheck Protection Program (PPP) under the U.S. Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”).

The PPP is a program administered by the U.S. Small Business Administration (“SBA”) that awards loans to help businesses keep their workforce employed during the Coronavirus (“COVID-19”) crisis. The company expects the loan to be forgiven in circumstances where it maintains or quickly rehires employees and maintains salary levels and where the funds are used for payroll costs, interest on mortgages, rent, and utilities, and at least 75% of the forgiven amount is used for payroll.

Additional terms of the loan under the PPP

Loan payments will also be deferred for six months. No collateral or personal guarantees are required. Neither the government nor lenders will charge small businesses any fees.

If any portion of the loan is not forgiven, the loan has a maturity of 2 years and an interest rate of 1%.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor Relations Contact:

Mike Bassett, ImpediMed

T : +61 407 431 432

E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@we-worldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.